Holly Tao

Associate, New York

Biography

Overview

Holly Tao is a member of the Firm’s Global Antitrust/Competition Group. Her practice focuses on complex litigation in the areas of antitrust and patent law.

She represents global pharmaceutical companies in nationwide, antitrust class-action lawsuits and in licensing and contractual disputes. Her litigation practice also includes cases arising under the Biologics Price Competition and Innovation Act and the Hatch-Waxman Act. She counsels clients on competition-risk issues, including government investigations and patent invalidity and infringement assessments.

Holly is also active in the Firm's pro bono work. She represents individuals and organizations at both trial and appellate courts, and has litigated matters regarding US constitutional rights as well as cases brought under Title VII of the Civil Rights Act and the Individuals with Disabilities Education Act.

Bars and Courts
New York State Bar
US District Court for the Eastern District of New York
US District Court for the Southern District of New York
US Court of Appeals for the Federal Circuit
US Supreme Court
Education
JD
Cornell University
BS
Chemistry
Georgetown University
Languages
English

Experience

Defense of a global pharmaceutical company in a nationwide antitrust class-action lawsuit regarding an exclusive license agreement relating to Botox® Cosmetic.

Defense of a global pharmaceutical company in a complex antitrust class-action lawsuit concerning its portfolio of small-molecule HIV products and its patent-settlement and collaboration agreements.

Defense of a global pharmaceutical company in a litigation arising from the Biologics Price Competition and Innovation Act relating to its biosimilar oncology product.

Representation of a global pharmaceutical company in the “patent dance” framework under the Biologics Price Competition and Innovation Act relating to a biosimilar product.

Representation of a global pharmaceutical company in a litigation arising from a contract dispute relating to small-molecule oncology products.

Representation of innovator pharmaceutical companies in a litigation arising under the Hatch-Waxman Act relating to a topical pain-medication product.

Publications

Congress, Courts, and Control Over Persuasive Sources of Law, Gonzaga Law Review, 2016